STOCK TITAN
  1. Home
  2. News
  3. PFE

Pfizer Inc. - PFE STOCK NEWS

Welcome to our dedicated news page for Pfizer (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pfizer's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pfizer's position in the market.

News
ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship to Improve HIV Prevention in Key Communities
Rhea-AI Summary
ViiV Healthcare, Pfizer, and Shionogi launch The Dr. Dawn K. Smith HIV Prevention Clinical Fellowship to train U.S. healthcare providers on PrEP for key populations. The fellowship aims to address disparities in HIV incidence and improve access to preventative care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
-
News
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
Rhea-AI Summary
ViiV Healthcare, in collaboration with Pfizer and Shionogi, announced positive results from a phase I study on a new ultra long-acting formulation of cabotegravir (CAB-ULA) for HIV treatment. The study showed that CAB-ULA can be dosed at intervals of at least four months, supporting a longer dose interval with promising safety and pharmacokinetic profiles. The findings were presented at CROI 2024, indicating a potential shift towards ultra long-acting HIV treatment regimens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
clinical trial
-
News
Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth
Rhea-AI Summary
Pfizer unveils strategic vision for its newly formed Oncology organization following Seagen acquisition, highlighting a robust portfolio with 8+ potential blockbuster medicines by 2030. The company aims to drive sustainable growth through near- and mid-term catalysts, focusing on core scientific modalities and key cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
News
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
Rhea-AI Summary
Pfizer Inc. announces positive top-line data for ABRYSVO vaccine efficacy against RSV in adults 60 and older, showing 77.8% efficacy against lower respiratory tract disease after two seasons. The vaccine demonstrated durable efficacy for both RSV A and RSV B, with consistent protection levels above 80% for severe symptoms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
none
-
News
ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
Rhea-AI Summary
ViiV Healthcare, a leading HIV specialist company, presented 64 abstracts at CROI 2024, showcasing advancements in their pipeline and portfolio, including ultra long-acting medicines, broadly neutralising antibodies, and real-world evidence. Key highlights include phase I study results of cabotegravir formulations, phase IIa findings of VH3810109, and interim analysis of the LATITUDE trial showing superior efficacy of Cabenuva over daily oral standard of care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences
-
News
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Rhea-AI Summary
Pfizer Inc. (PFE) will host a webcast with CFO David Denton at the TD Cowen 44th Annual Health Care Conference on March 4, 2024. The webcast will be available for replay for at least 90 days on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
conferences
News
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
Rhea-AI Summary
Pfizer Inc. and Everest Medicines' partner, Pfizer Inc., received marketing authorization from the European Commission for VELSIPITY® (etrasimod) in the EU to treat ulcerative colitis patients 16 years and older. The approval is based on positive Phase 3 data and offers a convenient once-daily oral treatment option for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
-
News
European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
Rhea-AI Summary
Pfizer Inc. receives marketing authorization from the European Commission for VELSIPITY, the first oral therapy for ulcerative colitis in the EU, targeting patients 16 years and older. The drug is approved for patients with moderately to severely active UC who haven't responded well to conventional or biological therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
Rhea-AI Summary
Pfizer Inc. (PFE) will host an Oncology Innovation Day to discuss its new Pfizer Oncology Division's strategic approach, robust portfolio, R&D capabilities, and growth potential until 2030. Investors can access the live webcast on February 29, 2024, and submit questions for the leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
News
ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)
Rhea-AI Summary
ViiV Healthcare, majority owned by GSK, with Pfizer and Shionogi as shareholders, announced the availability of Dovato in a blister pack in the U.S. Dovato is approved as a complete regimen to treat HIV-1 infection in adults with no ARV treatment history or to replace the current ARV regimen in those who are virologically suppressed. The blister pack aims to address challenges faced by the HIV community, offering discretion and portability for people living with HIV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
none
Stock PFE logo
Pfizer Inc.

NYSE:PFE

PFE Rankings

#73 Ranked by Market Cap
#4118 Ranked by Stock Gains
#440 Ranked by Dividends

PFE Stock Data

146.43B
5.64B
0.05%
69.93%
1.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Palo Alto

About PFE

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.